Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

about

Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.

P2860

Q47952363-860255C0-B7DD-48A3-B858-539B4C615C14

P2860

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

Item

http://www.wikidata.org/entity/Q48364794

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@en

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@nl

type

Item

label

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@en

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@nl

prefLabel

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@en

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@nl

P1476

Efficacy and toxicity of thera ...... in relapsed multiple myeloma.

@en

P2093

David B Page

http://www.w3.org/2001/XMLSchema#string

Deepika Cattry

http://www.w3.org/2001/XMLSchema#string

Emma C Scott

http://www.w3.org/2001/XMLSchema#string

Hani Hassoun

http://www.w3.org/2001/XMLSchema#string

Ivan M Borrello

http://www.w3.org/2001/XMLSchema#string

Martin Gutierrez

http://www.w3.org/2001/XMLSchema#string

Nikoletta Lendvai

http://www.w3.org/2001/XMLSchema#string

Stephen M Ansell

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Allogeneic hematopoietic cell transplantation for multiple myeloma.

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.

P304

221-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1320713

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28554253

http://www.w3.org/2001/XMLSchema#string

P932

5645787

http://www.w3.org/2001/XMLSchema#string

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

about

P2860

P2860

Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932